
|Articles|March 6, 2007
siRNA candidate enters the clinic
SR Pharma has launched a Phase I clinical trial of RTP-801i.
Advertisement
SR Pharma has launched a Phase I clinical trial of RTP-801i, a small interfering RNA (siRNA) therapeutic product licensed from Atugen AG, a subsidiary of SR Pharma.
RTP-801i is based on Atugen's proprietary siRNA technology that modifies the expression of one specific gene target involved in the progression of age-related macular degeneration (AMD).
Pfizer, who licensed the product in September of last year, is funding the trial.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Retinal imaging as a window into atrial fibrillation
2
The Wills Retina Report: Mapping gene therapy for wet AMD with Carl D. Regillo, MD, and Allen C. Ho, MD
3
Think outside the cone: Applying the Gulani Keratoconus Classification
4

















